SCIRP Mobile Website
Paper Submission

Why Us? >>

  • - Open Access
  • - Peer-reviewed
  • - Rapid publication
  • - Lifetime hosting
  • - Free indexing service
  • - Free promotion service
  • - More citations
  • - Search engine friendly

Free SCIRP Newsletters>>

Add your e-mail address to receive free newsletters from SCIRP.

 

Contact Us >>

WhatsApp  +86 18163351462(WhatsApp)
   
Paper Publishing WeChat
Book Publishing WeChat
(or Email:book@scirp.org)

Article citations

More>>

Baigent, C., et al. (2005) Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data from 90,056 Participants in 14 Randomised Trials of Statins. The Lancet, 366, 1267-1278. http://dx.doi.org/10.1016/S0140-6736(05)67394-1

has been cited by the following article:

  • TITLE: Resveratrol—The “Chateau Hormone” for Cardio Diabetic Protection

    AUTHORS: Manish Maladkar, Meenu Awatramani, Kundan Bhong

    KEYWORDS: Resveratrol, Cardiovascular Disease, Atherosclerosis, HDL-C, Diabetes, β-Blockers, Residual Vascular Risk

    JOURNAL NAME: Journal of Diabetes Mellitus, Vol.4 No.4, November 27, 2014

    ABSTRACT: Resveratrol is a naturally occurring phenolic compound abundantly found in grape skin and inwines. Resveratrol is a phytoalexin trans-3,5,4’-trihydroxystilbene that possesses diverse biochemicaland physiological actions. It is effective in improving health and preventing or treating chronicdiseases. The cardiovascular protective effects of Resveratrol suggest the anti-atherogenic and anti-inflammatory activity of the compound on endothelial cells. Resveratrol attenuates myocardial ischemic reperfusion injury, atherosclerosis and reduces ventricular arrhythmias. Resveratrol has been widely studied and is shown to have anti-oxidant, anti-inflammatory, anti-proliferative andanti-angiogenic effects and many signalling pathways are among the molecular targets of Resveratrol.Based on these mechanistic considerations, the involvement of Resveratrol has been observed in cardiovascular diseases, cancer and neurodegenerative diseases. In type 2 diabetes patients, when Resveratrol was given along with anti-diabetic agents, it was found to lower blood glucose, HbA1C and increase the insulin sensitivity and the levels of HDL-C. Resveratrol acts on the SIRT1 gene and stimulates endogenous pathways to promote health and longevity.